AMLX
Amylyx Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +9.1% ·
aandelenstroom +30.0% ·
netto nieuwe posities +8.3%
— formule
Brede accumulatie — stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q1 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 79 | +11 | 60.68M | $1.09B | +14 | −2 |
| Q1 2026 | 70 | -3 | 62.54M | $868.96M | +6 | −9 |
| Q4 2025 | 73 | 0 | 62.47M | $754.72M | — | — |
| Q3 2025 | 18 | +1 | 42.12M | $572.37M | +1 | — |
| Q2 2025 | 14 | -1 | 33.34M | $213.68M | — | −1 |
| Q1 2025 | 12 | +1 | 15.66M | $55.46M | +2 | −1 |
| Q4 2024 | 11 | 0 | 5.41M | $20.47M | +1 | −1 |
| Q3 2024 | 10 | +2 | 5.23M | $16.93M | +2 | — |
| Q2 2024 | 8 | — | 10.16M | $19.31M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 5.70M | Nieuw | $20.17M | 0.0% | New | 1 | SEC ↗ |
| 2 | Millennium Management ✦ | 3.08M | +418.6% | $10.91M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 2.76M | +39.9% | $9.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 2.76M | +39.9% | $9.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Point72 Asset Management ✦ | 916.97K | Nieuw | $3.25M | 0.0% | New | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passief) | 806.16K | +42.0% | $2.85M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passief) | 806.16K | +42.0% | $2.85M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 762.05K | +17.0% | $2.70M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 515.10K | +10.9% | $1.82M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 290.68K | +38.6% | $1.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 290.68K | +38.6% | $1.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 270.01K | -12.0% | $955,821 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 270.01K | -12.0% | $955,821 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | State Street Global Advisors ✦ (passief) | 261.78K | +19.9% | $926,712 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Marshall Wace ✦ | 247.28K | +33.9% | $875,353 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 57.70K | 0.0% | $205,000 | 0.0% | Held | 4 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Adage Capital Partners | $20.17M | 0.0% |
| Point72 Asset Management | $3.25M | 0.0% |
Verlaten
| AQR Capital Management | $712,099 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 170 houders, 113.99M aandelen, $1.58B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.